ArticleCell death and differentiation2026
Matrix stiffness-induced YEATS2 drives HCC progression via epigenetic activation of the TGFBR2-TAZ-AKT pathway.
Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
YEATS2, a crucial component of histone acetyltransferase (HAT) complexes, has been identified as overexpressed in multiple human cancers and is correlated with tumor advancement and unfavorable clinical outcomes. The precise role of YEATS2 in hepatocellular carcinoma (HCC) remains to be fully elucidated. This study seeks to investigate the function and mechanisms by which YEATS2 facilitates HCC growth and metastasis. Our results demonstrate that YEATS2 expression is markedly elevated in HCC tissues and is correlated with unfavorable clinical characteristics and decreased survival rates. Functional assays conducted both in vitro and in vivo reveal that YEATS2 enhances HCC cell proliferation, migration, and invasion. Through RNA sequencing and mass spectrometry analyses, this study revealed YEATS2 activates the TAZ/AKT signaling pathway and promotes aerobic glycolysis via the upregulation of TGFBR2. Chromatin immunoprecipitation and co-immunoprecipitation assays further confirm that YEATS2 interacts with KAT2A, leading to increased levels of H3K9ac and H3K14ac within the promoter region of TGFBR2, thereby promoting its transcriptional activation. Moreover, increased matrix stiffness was found to induce YEATS2 expression through augmenting the binding of HIF-1α to the YEATS2 promoter. Collectively, these results delineate a novel YEATS2-TGFBR2-TAZ-AKT signaling axis that connects matrix stiffness to metabolic reprogramming and HCC progression, highlighting YEATS2 as a potential therapeutic target for HCC.
Indexed as
Identifiers
41776086What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.